GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cyclically Adjusted FCF per Share

Biogen (BUE:BIIB) Cyclically Adjusted FCF per Share : ARS2,232.77 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biogen's adjusted free cash flow per share for the three months ended in Mar. 2025 was ARS1,543.063. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS2,232.77 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Biogen's average Cyclically Adjusted FCF Growth Rate was 1.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 7.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 18.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Biogen was 157.10% per year. The lowest was 7.00% per year. And the median was 25.35% per year.

As of today (2025-05-28), Biogen's current stock price is ARS11575.00. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was ARS2,232.77. Biogen's Cyclically Adjusted Price-to-FCF of today is 5.18.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogen was 88.05. The lowest was 5.21. And the median was 19.78.


Biogen Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Biogen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Cyclically Adjusted FCF per Share Chart

Biogen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 167.83 278.92 491.97 1,570.63 1,977.25

Biogen Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,818.85 2,273.68 2,097.76 1,977.25 2,232.77

Competitive Comparison of Biogen's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.


;
;

Biogen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1543.063/134.9266*134.9266
=1,543.063

Current CPI (Mar. 2025) = 134.9266.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 35.367 100.684 47.395
201509 26.675 100.392 35.851
201512 61.490 99.792 83.139
201603 57.291 100.470 76.939
201606 56.709 101.688 75.245
201609 48.313 101.861 63.996
201612 102.172 101.863 135.336
201703 -59.269 102.862 -77.744
201706 65.766 103.349 85.860
201709 111.619 104.136 144.623
201712 110.078 104.011 142.797
201803 119.200 105.290 152.753
201806 100.398 106.317 127.415
201809 281.634 106.507 356.784
201812 314.428 105.998 400.241
201903 264.383 107.251 332.607
201906 417.012 108.070 520.647
201909 487.242 108.329 606.870
201912 568.806 108.420 707.867
202003 432.298 108.902 535.608
202006 784.375 108.767 973.023
202009 518.074 109.815 636.544
202012 -247.203 109.897 -303.505
202103 400.066 111.754 483.019
202106 729.188 114.631 858.289
202109 489.163 115.734 570.281
202112 527.065 117.630 604.568
202203 75.582 121.301 84.072
202206 574.242 125.017 619.761
202209 577.583 125.227 622.323
202212 -302.554 125.222 -326.002
202303 522.038 127.348 553.106
202306 659.794 128.729 691.561
202309 1,219.991 129.860 1,267.595
202312 -130.395 129.419 -135.944
202403 2,496.318 131.776 2,555.998
202406 3,579.545 132.554 3,643.621
202409 5,241.087 133.029 5,315.853
202412 4,808.403 133.157 4,872.301
202503 1,543.063 134.927 1,543.063

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Biogen  (BUE:BIIB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=11575.00/2232.77
=5.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogen was 88.05. The lowest was 5.21. And the median was 19.78.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biogen Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Biogen's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen Business Description

Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.